Contributor since: 2015
Biogen Is The Ultimate Value Trap
Gilead: Hold For Now
Resist The Urge To 'Chill' With Netflix Following Lackluster First-Quarter Results
Is The Failed Oil Production Cut Agreement The Downside Catalyst Everyone Has Been Looking For?
Why The Termination Of The Allergan-Pfizer Deal Isn't Too Bad After All
The End Is In Sight For MannKind
Flexion's Zilretta Is Destined To Transpire As A Commercial Flop
2 Vital Lessons From Ackman's Blunder On Valeant
Short Regeneron: Further Downside Ahead For This Bloated Large-Cap Pharma Trading At An Unjustifiable Premium
Gilead: Competition Worries Are Overblown
MannKind's Bear Thesis Remains Intact As Woes Continue
Dynavax: Increased Conviction In Heplisav's Chances For Approval
Puma Biotechnology: Neratinib Is Being Misunderstood
Mannkind: Afrezza Is Not The Next Big Thing In Inhalable Insulin
Biotech Meltdown: Bargains To Target On This Decline
Medivation: A Beaten Down Biotech With Major Growth Potential
Clovis Oncology: Don't Discount Rociletinib's Chances Against AZD9291
Gilead's Next Big Acquisition: Where Will They Expand?
ACADIA Pharmaceuticals: Developing Late-Stage Assets With Blockbuster Potential
Bluebird Bio: Transforming The Gene Therapy Landscape In Rare Diseases
Achillion-Janssen Deal Boosts Achillion's Progress In Competing In Hepatitis-C
Intercept Pharmaceuticals: Serving Unmet Needs With Blockbuster Potential
Radius Health: Flying Under The Radar With An Exceptional Pipeline
Receptos: Unleashing The Beast
Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
Celldex: An Immuno-Oncology Play With Monster Potential
Cempra: Reviving The Antibiotic Market
Vipshop: The Gift That Keeps On Giving
Achillion Pharmaceuticals: A Strong Contender In A Crowded Space